Indoximod
- Generic Name
- Indoximod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H14N2O2
- CAS Number
- 110117-83-4
- Unique Ingredient Identifier
- TX5CYN1KMZ
- Background
Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Theodore S. Johnson
- Target Recruit Count
- 37
- Registration Number
- NCT05106296
- Locations
- 🇺🇸
Augusta University, Georgia Cancer Center, Augusta, Georgia, United States
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT03301636
- Locations
- 🇺🇸
Utah Cancer Specialists, Salt Lake City, Utah, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT02502708
- Locations
- 🇺🇸
Children's Heathcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT02460367
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 157
- Registration Number
- NCT02077881
- Locations
- 🇺🇸
University of Kentucy, Lexington, Kentucky, United States
🇺🇸Greenville Health Systems, Greenville, South Carolina, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT02073123
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT02052648
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸University Cancer and Blood Center, Athens, Georgia, United States
🇺🇸UC Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 169
- Registration Number
- NCT01792050
- Locations
- 🇵🇱
Research Site, Warsaw, Poland
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
- Conditions
- Interventions
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01191216
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Billings Clinic, Billings, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.